Drugs / Doravine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06719570 | Jan → Mar 2024 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Doravine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06719570 ↗ |
| Route | Oral | “Oral tablet” NCT06719570 ↗ |